Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 8, 2011, Pages 925-927

  Alkemade, Gonnie M ^a,b   Hilbrands, Robert ^a,c   Vandemeulebroucke, Evy ^a,c   Pipeleers, Daniel ^a,c   Waldmann, Herman ^d   Mathieu, Chantal ^a,e   Keymeulen, Bart ^a,c   Roep, Bart O ^a,b  

^a Juvenile Diabetes Research Foundation Center for ß Cell Therapy in Diabetes   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c DIABETES RESEARCH CENTER   (Belgium)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Anti CD3; Immune memory; Immunotherapy; Intervention; Otelixizumab; T1DM

Indexed keywords

AUTOANTIGEN; BACTERIAL ANTIGEN; FUNGUS ANTIGEN; OTELIXIZUMAB; PLACEBO; PROTEIN P53; VIRUS ANTIGEN;

ABSENCE OF SIDE EFFECTS; ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HUMAN CELL; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE PROLIFERATION; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECALL IMMUNITY; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TUMOR IMMUNITY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD3; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC MEMORY;

EID: 80855124117     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1273     Document Type: Article

References (10)

1. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994; 91: 123-127.
2. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-2608.
3. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomized controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010; 53: 614-623.
4. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346: 1692-1698.
5. Keymeulen B, Candon S, Fafi-Kremer S, et al. Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood 2010; 115: 1145-1155.
6. Van de Linde P, Van der Boog PJM, Tysma OMH, et al. Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin. Clin Exp Immunol 2007; 149: 56-62.
7. Monti P, Scirpoli M, Maffi P, et al. Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells. J Clin Invest 2008; 118: 1806-1814.
8. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7: 622-632.
9. Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8 + CD25+ Tregs. J Clin Invest 2005; 115: 2904-2913.
10. Van de Linde P, Tysma OMH, Medema JP, et al. Mechanisms of antibody immunotherapy on clonal islet reactive T cells. Human Immunol 2006; 67: 264-273.